CHICAGO, Illinois – The U.S. introduction of drug-eluting stents, made possible by the FDA’s late-April approval of the Cypher stent from Johnson & Johnson’s (New Brunswick, New Jersey) Cordis (Miami Lakes, Florida) unit, will open a new chapter in the history of interventional cardiology and drive significant changes in medical practice as well as in market share for suppliers.